Although
vascular endothelial growth factor receptor (
VEGF-R)-targeted
antiangiogenic agents are important treatment for a number of human
malignancies, there is accumulating evidence that the
therapies may promote
disease progression, such as invasion and
metastasis. How
tumors become to promote their evasiveness remains fully uncertain. One of possible mechanisms for the adaptation may be a direct effect of
VEGF-R inhibitors on
tumor cells expressing
VEGF-R. To elucidate a direct effect of
VEGF-R-targeting drug (
sunitinib), we established a human
colorectal cancer cell model adapted to
sunitinib. The
sunitinib-conditioned cells showed a significant increase in cellular motility and migration activities, compared to the vehicle-treated control cells. Consistent with the phenotype, the
sunitinib-conditioned cells decreased the expression levels of
E-cadherin (an epithelial marker), while significantly increased the levels of Slug and Zeb1 (mesenchymal markers). Expression profiles of
VEGF-R in the
sunitinib-conditioned cells showed that only
neuropilin-1 (NRP1) expression was significantly increased among all
VEGF-R tested. Blockade of NRP1 using its antagonist clearly repressed the migration activation in
sunitinib-conditioned cells, but not in the control cells. These results suggest that inhibition of
VEGF-R on
colorectal cancer cells can drive the epithelial-mesenchymal transition, leading to activation of cell motility in an NRP1-dependent manner. J. Med. Invest. 64: 250-254, August, 2017.